The Use of Dye-less Cystoscopy in Assessing Urinary Tract Integrity During Hysterectomy
NCT ID: NCT05190939
Last Updated: 2023-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
276 participants
INTERVENTIONAL
2018-07-01
2019-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After Hysterectomy
NCT02751073
Optimization of Ureterolysis During Hysterectomy
NCT03123315
"Laparoscopic" Cystoscopy Versus Traditional Cystoscopy
NCT01261819
Ultrasound for Assessment of Intra-Abdominal Blood Loss After Gynecological Surgery
NCT06953141
Postoperative Bladder Testing After Total Laparoscopic Hysterectomy
NCT03126162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intra-operative detection of urinary tract injury enables primary repair with high rates of success and avoidance of morbidity. Currently however, there is no standard recommendation for the routine use of cystoscopy in general gynecologic surgeries or in patients undergoing hysterectomy for gynecologic malignancies. Cost appears to be the main reason for the lack of a policy level endorsement of routine cystoscopy. One analysis concluded that ureteral injury rate was too low to justify routine cystoscopy, however other studies have reported higher urinary tract injury rates than previously published data, noted especially with the increasing use minimally invasive surgery.
Removal of dye usage with cystoscopy can help mitigate the issue of cost associated with routine cystoscopy. Various dye agents are used to aid in the visualization of urine efflux. Multiple studies have evaluated the pros and cons of these dyes. The ability to perform cystoscopy without dye would decrease cost, if the accuracy of urinary tract injury identification is not compromised. The primary objective of this study is to assess the accuracy of dye-less cystoscopy in the detection of urinary tract injury following hysterectomy. The investigators hypothesize that accurate cystoscopic evaluation for urinary tract injury at hysterectomy can be accomplished without the use of dye.
This study is a randomized prospective evaluation in which patients undergoing hysterectomy for both benign and malignant conditions are randomized into one of four study arms: 1) dye/saline 2) dye/water 3) no-dye/saline and 4) no-dye/water. Following completion of hysterectomy patients undergo routine cystoscopy utilizing distending media and dye (or no dye) according to their assigned randomization. Two independent and blinded evaluations of the bilateral ureteral jet strengths is then performed using a continuous visual scale scoring system. Ureteral jet strength scores are then evaluated for inter-observer correlation as well as comparison of jet strength and time until initial ureteral jetting is seen between the four randomized arms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
no-dye/saline
Subjects assigned to the no-dye/saline group will have cystoscopy performed using saline as the bladder distending media and will not utilize any intravenous dye
No intervention
Saline only, no dye
dye/saline
Subjects assigned to the dye/saline group will have cystoscopy performed using saline as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
intravenous dye
intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
no-dye/water
Subjects assigned to the no-dye/water group will have cystoscopy performed using water as the bladder distending media and will not utilize any intravenous dye
water as bladder distending media
water will be used for bladder dissension during cystoscopy
dye/water
Subjects assigned to the dye/water group will have cystoscopy performed using water as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
water as bladder distending media
water will be used for bladder dissension during cystoscopy
intravenous dye
intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
water as bladder distending media
water will be used for bladder dissension during cystoscopy
intravenous dye
intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
No intervention
Saline only, no dye
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects undergoing hysterectomy for benign or malignant indications
Exclusion Criteria
* Inability to provide informed consent
* Subject is not a surgical candidate
18 Years
90 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
WellSpan Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eav Lim
Site Director, Gynecology Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Okechukwu Ibeanu, MD
Role: PRINCIPAL_INVESTIGATOR
WellSpan Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wellspan Health
York, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ibeanu OA, Chesson RR, Echols KT, Nieves M, Busangu F, Nolan TE. Urinary tract injury during hysterectomy based on universal cystoscopy. Obstet Gynecol. 2009 Jan;113(1):6-10. doi: 10.1097/AOG.0b013e31818f6219.
Dowling RA, Corriere JN Jr, Sandler CM. Iatrogenic ureteral injury. J Urol. 1986 May;135(5):912-5. doi: 10.1016/s0022-5347(17)45921-0.
Chou MT, Wang CJ, Lien RC. Prophylactic ureteral catheterization in gynecologic surgery: a 12-year randomized trial in a community hospital. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun;20(6):689-93. doi: 10.1007/s00192-008-0788-3. Epub 2009 Jan 23.
Redan JA, McCarus SD. Protect the ureters. JSLS. 2009 Apr-Jun;13(2):139-41.
Frankel J. Accuracy of cystoscopy in the diagnosis of ureteral injury in benign gynecologic surgery. Int Urogynecol J Pelvic Floor Dysfunct. 2004 Mar-Apr;15(2):75. doi: 10.1007/s00192-004-1144-x. Epub 2004 Feb 20. No abstract available.
Gilmour DT, Das S, Flowerdew G. Rates of urinary tract injury from gynecologic surgery and the role of intraoperative cystoscopy. Obstet Gynecol. 2006 Jun;107(6):1366-72. doi: 10.1097/01.AOG.0000220500.83528.6e.
Teeluckdharry B, Gilmour D, Flowerdew G. Urinary Tract Injury at Benign Gynecologic Surgery and the Role of Cystoscopy: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015 Dec;126(6):1161-1169. doi: 10.1097/AOG.0000000000001096.
Barber EL, Polan RM, Strohl AE, Siedhoff MT, Clarke-Pearson DL. Cystoscopy at the Time of Hysterectomy for Benign Indications and Delayed Lower Genitourinary Tract Injury. Obstet Gynecol. 2019 May;133(5):888-895. doi: 10.1097/AOG.0000000000003192.
American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 372. July 2007. The Role of cystourethroscopy in the generalist obstetrician-gynecologist practice. Obstet Gynecol. 2007 Jul;110(1):221-224. doi: 10.1097/01.AOG.0000263916.77694.20.
Visco AG, Taber KH, Weidner AC, Barber MD, Myers ER. Cost-effectiveness of universal cystoscopy to identify ureteral injury at hysterectomy. Obstet Gynecol. 2001 May;97(5 Pt 1):685-92. doi: 10.1016/s0029-7844(01)01193-0.
Vakili B, Chesson RR, Kyle BL, Shobeiri SA, Echols KT, Gist R, Zheng YT, Nolan TE. The incidence of urinary tract injury during hysterectomy: a prospective analysis based on universal cystoscopy. Am J Obstet Gynecol. 2005 May;192(5):1599-604. doi: 10.1016/j.ajog.2004.11.016.
Espaillat-Rijo L, Siff L, Alas AN, Chadi SA, Zimberg S, Vaish S, Davila GW, Barber M, Hurtado EA. Intraoperative Cystoscopic Evaluation of Ureteral Patency: A Randomized Controlled Trial. Obstet Gynecol. 2016 Dec;128(6):1378-1383. doi: 10.1097/AOG.0000000000001750.
Siff LN, Unger CA, Jelovsek JE, Paraiso MF, Ridgeway BM, Barber MD. Assessing ureteral patency using 10% dextrose cystoscopy fluid: evaluation of urinary tract infection rates. Am J Obstet Gynecol. 2016 Jul;215(1):74.e1-6. doi: 10.1016/j.ajog.2016.02.006. Epub 2016 Feb 12.
Grimes CL, Patankar S, Ryntz T, Philip N, Simpson K, Truong M, Young C, Advincula A, Madueke-Laveaux OS, Walters R, Ananth CV, Kim JH. Evaluating ureteral patency in the post-indigo carmine era: a randomized controlled trial. Am J Obstet Gynecol. 2017 Nov;217(5):601.e1-601.e10. doi: 10.1016/j.ajog.2017.07.012. Epub 2017 Jul 18.
Propst K, Tunitsky-Bitton E, O'Sullivan DM, Steinberg AC, LaSala C. Phenazopyridine for Evaluation of Ureteral Patency: A Randomized Controlled Trial. Obstet Gynecol. 2016 Aug;128(2):348-355. doi: 10.1097/AOG.0000000000001472.
Strom EM, Chaudhry ZQ, Guo R, Maisonet AJ, Holschneider CH, Wieslander CK. Effectiveness of Assessing Ureteral Patency Using Preoperative Phenazopyridine. Female Pelvic Med Reconstr Surg. 2019 Jul/Aug;25(4):289-293. doi: 10.1097/SPV.0000000000000540.
Hui JYC, Harvey MA, Johnston SL. Confirmation of ureteric patency during cystoscopy using phenazopyridine HCl: a low-cost approach. J Obstet Gynaecol Can. 2009 Sep;31(9):845-849. doi: 10.1016/S1701-2163(16)34303-1.
Cohen SA, Chaudhry Z, Oliver JL, Kreydin EI, Nguyen MT, Mills SA, Ackerman AL, Kim JH, Tarnay CM, Raz S. Comparison of Times to Ureteral Efflux after Administration of Sodium Fluorescein and Phenazopyridine. J Urol. 2017 Feb;197(2):519-523. doi: 10.1016/j.juro.2016.07.099. Epub 2016 Sep 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1236245-7
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.